
CRNX Stock Forecast & Price Target
CRNX Analyst Ratings
Bulls say
Crinetics Pharmaceuticals Inc. has demonstrated a strong upward revision in revenue estimates for its lead product, Paltusotine, with projections for 2026 rising to approximately $100 million from a previous estimate of $43 million, highlighting robust demand and pricing strength. The company reported over $5 million in net product revenue for Paltusotine in 4Q25, exceeding prior estimates and underscoring stronger-than-expected sales performance. Furthermore, the early positive responses from patients, with symptom improvement within the first 2-4 weeks of treatment, create a favorable outlook for patient adoption and sustained revenue growth as the company progresses through its developmental milestones.
Bears say
Crinetics Pharmaceuticals faces significant challenges that contribute to a negative outlook on its stock, primarily centered around financial and commercial viability concerns. The company is projected to incur net losses until at least the commercialization phase, indicating ongoing financial strain and uncertainty. Additionally, potential obstacles to commercial uptake exist due to the lack of differentiation of its products from existing therapies, compounded by recent reductions in peak sales estimates that reflect a more cautious market approach.
This aggregate rating is based on analysts' research of Crinetics Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
CRNX Analyst Forecast & Price Prediction
Start investing in CRNX
Order type
Buy in
Order amount
Est. shares
0 shares